Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label Study to Evaluate PF-08046044/SGN-35C in Adults With Advanced Malignancies.

NCT06254495 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT06254495
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06254495 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label Study to Evaluate PF-08046044/SGN-35C in Adults With Advanced Malignancies.
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
May 28, 2024
Completion date
April 13, 2026
Enrollment
58 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin disease, lymphoma, large b-cell, diffuse, lymphoma, large-cell, anaplastic, lymphoma, t-cell, peripheral